Table 2.

Clonality of the MRSA clinical isolates from the HSJ (Oporto, Portugal)

Yr (n) and isolate no.mecA::Tn554:: PFGERAPD ERIC1/ERIC2No. of isolatesClonal type (n[%])Resistance to drugf:
SPCSXT
1990 (9)
 117aI::E::A1AA1I::E::A (2 [22])RS
 109aI::E::A3AA1
 103aIII::α::C2A′D1
 100III::α::C31
 114aIII::α::C6A′D1III::α::C (7 [78])RS
 110III::α::C81
 115III::α::C91
 112aIII::α::C7A′D1
 111aIII::α::C11A′D1
1991 (9)
 122,a 128, 129, 132,b133III::α::C1A′D5
 120III::α::C21III::α::C (8 [89])RS
 121aIII::α::C10A′D1
 124aIII::α::C12A′D1
 126aXIII::χ::DCE1XIII::χ::D (1 [11])RR
1992 (14)
 153, 154, 157, 160, 161I::E::A15I::E::A (7 [50])
 135I::E::A41RS
 146I::E::A51
 152aI::J::A2AA1I::J::A (1 [7])RS
 137, 142III::α::C12
 138III::α::C41III::α::C (5 [36])RS
 151III::α::C51
 159III::α::C61
 136aIII::α::EA′D1III::α::E (1 [7])RS
1996 (64)
 202, 221, 223I::E::A13
 204, 219, 222, 226, 227, 229, 232, 234, 261, 282, 309, 312I::E::A612
 210, 233, 244, 259I::E::A74I::E::A (32 [50])RS
 213,a 249, 250I::E::A8AA3
 216, 236, 248, 257, 258I::E::A95
 245,a276aI::E::A10AA2
 208,a217aI::E::A11AA2
 274I::E::A121
 212aI::J::A1AA1I::J::A (2 [3])RS
 262aI::J::A6AA1
 265aI::NH::A11AA1I::NH::A (1 [2])SS
 311aII::NH::FBC1II::NH::F (1 [2])SS
 200,a,c230,c 247, 264, 271, 291, 301,d 307, 315XI::B::B1A′D9
 228cXI::B::B31
 251,a,c 253, 255c,dXI::B::B4A′D3XI::B::B (21 [33])SR
 246,a252,e254XI::B::B5A′D3
 218,a,c240XI::B::B6A′D2
 272XI::B::B71
 290,a314aXI::B::B10A′D2
 256,a 284, 285,c,d288XI::B′::B14
 211a,cXI::B′::B2A′D1XI::B′::B (7 [10])SR
 295XI::B′::B81
 297XI::B′::B91
  • a Isolate assayed by RAPD.

  • b Exception: intermediately resistant to SXT.

  • c Exception: intermediately resistant to spectinomycin.

  • d Exception: susceptible to SXT.

  • e Exception: resistant to spectinomycin.

  • f SPC, spectinomycin; R, resistant; S, susceptible.